Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
THE APEX TIMES
THE APEX TIMES
The acquisition, announced as a move in biotech drug development, would expand Eli Lilly’s pipeline through the purchase of Merida Biosciences, with consideration structured as an up-to amount paid in cash.
THE APEX TIMES
The new U.S. label for tirzepatide (marketed as Mounjaro) extends its use beyond blood sugar control, giving Eli Lilly a broader commercial opportunity in a patient group already targeted by diabetes and cardiometabolic therapies.
THE APEX TIMES
The acquisition expands Lilly’s autoimmune and immunology pipeline, the company said, as it continues to supplement growth with targeted deals.
THE APEX TIMES
A market report highlights repeated setbacks in social anxiety research and points to Eli Lilly’s planned acquisition of AtaiBeckley as an attempt to break through a difficult clinical area.
THE APEX TIMES
The drugmaker said it struck a $2.9 billion agreement as it continues an aggressive acquisition pace, while also reporting new late-stage data on Zepbound in combination with Taltz for adults with psoriasis-related conditions who are obese.
THE APEX TIMES
The cash offer, announced Aug. 31, is designed to expand Eli Lilly’s immunology portfolio, according to a report.
THE APEX TIMES
The acquisition is aimed at expanding Eli Lilly’s antibody pipeline, including programs tied to Graves’ disease, thyroid eye disease and food allergy.
THE APEX TIMES
The acquisition, announced by Lilly, is designed to bolster its pipeline with an autoimmune-focused portfolio as the company continues to lean on growth beyond its core diabetes and oncology franchises.
